Cigna Investments’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.2M | Sell |
2,408
-26
| -1% | -$11.5K | 0.15% | 105 |
|
|
2026
Q1 | $1.09M | Sell |
2,434
-48
| -2% | -$22.4K | 0.17% | 110 |
|
|
2025
Q4 | $1.13M | Sell |
2,482
-39
| -2% | -$16.8K | 0.16% | 111 |
|
|
2025
Q3 | $987K | Sell |
2,521
-18
| -0.7% | -$7.52K | 0.14% | 125 |
|
|
2025
Q2 | $1.13M | Sell |
2,539
-63
| -2% | -$29K | 0.19% | 104 |
|
|
2025
Q1 | $1.26M | Sell |
2,602
-55
| -2% | -$25.6K | 0.23% | 89 |
|
|
2024
Q4 | $1.07M | Sell |
2,657
-14
| -0.5% | -$6.49K | 0.19% | 104 |
|
|
2024
Q3 | $1.24M | Sell |
2,671
-48
| -2% | -$23.1K | 0.22% | 87 |
|
|
2024
Q2 | $1.27M | Sell |
2,719
-18
| -0.7% | -$7.81K | 0.24% | 85 |
|
|
2024
Q1 | $1.14M | Sell |
2,737
-27
| -1% | -$11.4K | 0.22% | 98 |
|
|
2023
Q4 | $1.13M | Sell |
2,764
-14
| -0.5% | -$5.17K | 0.23% | 93 |
|
|
2023
Q3 | $966K | Sell |
2,778
-347
| -11% | -$121K | 0.22% | 98 |
|
|
2023
Q2 | $1.1M | Sell |
3,125
-1
| -0% | -$337 | 0.2% | 101 |
|
|
2023
Q1 | $985K | Sell |
3,126
-63
| -2% | -$18.9K | 0.2% | 109 |
|
|
2022
Q4 | $921K | Buy |
3,189
+4
| +0.1% | +$1.22K | 0.19% | 118 |
|
|
2022
Q3 | $922K | Sell |
3,185
-96
| -3% | -$27.6K | 0.2% | 101 |
|
|
2022
Q2 | $925K | Sell |
3,281
-1,208
| -27% | -$323K | 0.18% | 116 |
|
|
2022
Q1 | $1.17M | Sell |
4,489
-1,303
| -22% | -$309K | 0.14% | 139 |
|
|
2021
Q4 | $1.27M | Sell |
5,792
-2,242
| -28% | -$436K | 0.1% | 162 |
|
|
2021
Q3 | $1.46M | Sell |
8,034
-136
| -2% | -$26.6K | 0.11% | 163 |
|
|
2021
Q2 | $1.65M | Sell |
8,170
-1,175
| -13% | -$246K | 0.12% | 155 |
|
|
2021
Q1 | $2.01M | Buy |
9,345
+208
| +2% | +$45.7K | 0.14% | 135 |
|
|
2020
Q4 | $2.16M | Buy |
9,137
+730
| +9% | +$167K | 0.17% | 122 |
|
|
2020
Q3 | $2.29M | Sell |
8,407
-1,931
| -19% | -$533K | 0.22% | 87 |
|
|
2020
Q2 | $3M | Sell |
10,338
-2,293
| -18% | -$622K | 0.28% | 71 |
|
|
2020
Q1 | $3.01M | Sell |
12,631
-2,452
| -16% | -$562K | 0.39% | 56 |
|
|
2019
Q4 | $3.42M | Sell |
15,083
-774
| -5% | -$157K | 0.36% | 53 |
|
|
2019
Q3 | $3.1M | Buy |
15,857
+5,551
| +54% | +$982K | 0.32% | 67 |
|
|
2019
Q2 | $1.72M | Buy |
10,306
+870
| +9% | +$152K | 0.19% | 119 |
|
|
2019
Q1 | $1.74M | Sell |
9,436
-548
| -5% | -$101K | 0.19% | 108 |
|
|
2018
Q4 | $1.65M | Buy |
9,984
+16
| +0.2% | +$2.77K | 0.14% | 100 |
|
|
2018
Q3 | $1.69M | Sell |
9,968
-1,419
| -12% | -$253K | 0.14% | 111 |
|
|
2018
Q2 | $1.93M | Sell |
11,387
-1,162
| -9% | -$180K | 0.14% | 103 |
|
|
2018
Q1 | $2.04M | Sell |
12,549
-54
| -0.4% | -$8.82K | 0.14% | 109 |
|
|
2017
Q4 | $1.89M | Sell |
12,603
-207
| -2% | -$30.6K | 0.12% | 126 |
|
|
2017
Q3 | $1.95M | Buy |
12,810
+2,048
| +19% | +$308K | 0.13% | 117 |
|
|
2017
Q2 | $1.39M | Buy |
10,762
+504
| +5% | +$60.7K | 0.1% | 172 |
|
|
2017
Q1 | $1.12M | Buy |
10,258
+1,159
| +13% | +$102K | 0.08% | 243 |
|
|
2016
Q4 | $670K | Buy |
+9,099
| New | +$740K | 0.07% | 333 |
|
Other funds holding VRTX
Cigna Investments's VRTX Position: Q2 2026 in Review
Cigna Investments reduced its Vertex Pharmaceuticals (VRTX) stake by 1.1% in Q2 2026, selling an estimated $11.5K and leaving 2,408 shares worth $1.2M. The position accounts for 0.15% of the portfolio, ranked #105.
Cigna Investments first reported a position in VRTX in Q4 2016 and has held it in 39 quarters since. The position peaked at $3.42M in Q4 2019. 1,749 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Cigna Investments held 2,408 shares of Vertex Pharmaceuticals worth $1.2M as of Q2 2026.
- Cigna Investments sold 26 Vertex Pharmaceuticals shares in Q2 2026, an estimated $11.5K.
- Vertex Pharmaceuticals made up 0.15% of Cigna Investments's portfolio in Q2 2026, its #105 holding.
- Cigna Investments first reported a position in Vertex Pharmaceuticals in Q4 2016 and has held it in 39 quarters since.
- Cigna Investments's Vertex Pharmaceuticals position peaked at $3.42M in Q4 2019.
- 1,749 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Cigna Investments's 13F filing for Q2 2026, filed 21 Jul 2026.